|
| Press Releases |
|
 |
|
| Friday, July 12, 2024 |
|
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
| Thursday, July 11, 2024 |
|
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
| Tuesday, July 2, 2024 |
|
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
| Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
| Friday, June 28, 2024 |
|
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
| Friday, June 21, 2024 |
|
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
| Monday, June 10, 2024 |
|
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Monday, June 3, 2024 |
|
|
Eisai Named to List of The Time 100 Most Influential Companies |
| TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. more info >> |
|
|
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform |
| Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of discovering innovative technologies and services, supporting venture businesses with such technologies and partnering with those businesses in the future, so as to accelerate drug discovery innovation and the establishment of the ecosystem platform. more info >> |
|
| Tuesday, May 28, 2024 |
|
|
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD (early AD). more info >> |
|
| Thursday, May 23, 2024 |
|
|
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 |
| Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
First three HKTDC trade fairs of 2026 draw some 82,000 international buyers
Jan 15, 2026 19:46 HKT/SGT
|
|
|
NEC Launches "NEC Composable Disaggregated Infrastructure Solution" for Distributed Computing Resources
Jan 15, 2026 17:00 JST
|
|
|
A True Empowerer - AGFA HealthCare Radiates Imaging Innovation at ECR 2026
Jan 15, 2026 16:00 HKT/SGT
|
|
|
OPPO Appoints Stagwell (STGW) Agencies in Singapore: Allison Worldwide for PR and Influencer; Assembly for Media
Jan 15, 2026 14:00 HKT/SGT
|
|
|
Casa Minerals Inc. Announces Non-Brokered Private Placement Raising $800,000
Jan 15, 2026 01:29 HKT/SGT
|
|
|
Doubleview Confirms Metal Recoveries for Upcoming Mineral Resource Estimate and Preliminary Economic Assessment
Jan 14, 2026 21:59 HKT/SGT
|
|
|
Mitsubishi Power Lands Significant Gas Turbine Order for Qatar's Facility E IWPP Project
Jan 14, 2026 18:58 JST
|
|
|
Mitsubishi Motors Launches Updated Outlander PHEV in Canada
Jan 14, 2026 17:38 JST
|
|
|
SERES Lands on HKEX Today: Intelligence Redefines Luxury - The 'Tesla of China' Sets Sail for New Capital Blue Ocean
Jan 14, 2026 14:30 HKT/SGT
|
|
|
GBA enterprises speed up ASEAN expansion, amid trade tensions, with 73 percent fast-tracking plans
Jan 14, 2026 14:20 HKT/SGT
|
|
|
Hitachi High-Tech launches FOUNDRY-MASTER Smart 2, enhancing performance and value of stationary optical emission spectrometers
Jan 14, 2026 14:10 JST
|
|
|
DPC Dash - Domino's Pizza China Defies Headwinds in 2025 as Strong Q4 Performance Cements Market Leadership
Jan 14, 2026 13:00 HKT/SGT
|
|
|
The 20th PropertyGuru Asia Property Awards Grand Final recognises Singapore's finest real estate
Jan 14, 2026 13:00 HKT/SGT
|
|
|
Fujitsu launches demonstration experiment into green steel value flow utilizing blockchain technology to accelerate decarbonization in the steel Industry
Jan 14, 2026 10:52 JST
|
|
|
Toyota Systems, Fujitsu utilize quantum-inspired technology and AI to streamline on-board computer design and contribute to sustainable development
Jan 14, 2026 10:36 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
